<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>The <z:chebi fb="1" ids="35475">NSAID</z:chebi> (<z:chebi fb="2" ids="35475">non-steroidal anti-inflammatory drug</z:chebi>) <z:chebi fb="0" ids="49662">indomethacin</z:chebi>, a cyclo-oxygenase-1 and -2 inhibitor with anti-inflammatory and <z:chebi fb="29" ids="35480">analgesic</z:chebi> properties, is known to possess anticancer activity against <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> (<z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e>) and other <z:e sem="disease" ids="C0006826" disease_type="Neoplastic Process" abbrv="">malignancies</z:e> in humans; however, the mechanism underlying the anticancer action remains elusive </plain></SENT>
<SENT sid="1" pm="."><plain>In the present study we show that <z:chebi fb="0" ids="49662">indomethacin</z:chebi> selectively activates the dsRNA (double-stranded <z:chebi fb="40" ids="33697">RNA</z:chebi>)-dependent protein kinase PKR in a cyclo-oxygenase-independent manner, causing rapid phosphorylation of eIF2α (the α-subunit of eukaryotic translation initiation factor 2) and inhibiting protein synthesis in colorectal <z:mp ids='MP_0002038'>carcinoma</z:mp> and other types of <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> cells </plain></SENT>
<SENT sid="2" pm="."><plain>The PKR-mediated translational block was followed by inhibition of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> cell proliferation and <z:mpath ids='MPATH_3'>apoptosis</z:mpath> induction </plain></SENT>
<SENT sid="3" pm="."><plain><z:chebi fb="0" ids="49662">Indomethacin</z:chebi> did not affect the activity of the eIF2α kinases <z:chebi fb="1" ids="17300">PERK</z:chebi> (PKR-like endoplasmic reticulum-resident kinase), GCN2 (general control non-derepressible-2) and HRI (haem-regulated inhibitor kinase), and induced eIF2α phosphorylation in <z:chebi fb="1" ids="17300">PERK</z:chebi>-knockout and GCN2-knockout cells, but not in PKR-knockout cells or in human PKR-silenced <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> cells, identifying PKR as a selective target for <z:chebi fb="0" ids="49662">indomethacin</z:chebi>-induced translational inhibition </plain></SENT>
<SENT sid="4" pm="."><plain>The fact that <z:chebi fb="0" ids="49662">indomethacin</z:chebi> induced PKR activity in vitro, an effect reversed by the PKR inhibitor <z:chebi fb="0" ids="20702">2-aminopurine</z:chebi>, suggests a direct effect of the drug in kinase activation </plain></SENT>
<SENT sid="5" pm="."><plain>The results of the present study identify PKR as a novel target of <z:chebi fb="0" ids="49662">indomethacin</z:chebi>, suggesting new scenarios on the molecular mechanisms underlying the pleiotropic activity of this traditional <z:chebi fb="1" ids="35475">NSAID</z:chebi> </plain></SENT>
</text></document>